×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Dr. Mazyar Shadman
“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE®.
 
Dr. Mazyar Shadman
“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”
 
Ryan McDonald and Dr. Mazyar Shadman
In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.
 
Ryan McDonald and Dr. Mazyar Shadman
In an interview with CURE®, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.
 
Ryan McDonald and Mazyar Shadman
There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.
 
CURE Staff
Here is a list of the recent trial initiations that occurred within the cancer space in June.
 
Dr. Brian Koffman
Regulation changes could eliminate barriers to potentially lifesaving CAR-T cell immunotherapy for patients covered by Medicare or Medicaid.
 
Conor Killmurray
From a study showing a popular cancer side effect management steroid decreasing the risk of death for patients in the hospital with COVID-19 to a new liquid biopsy test detecting lingering cancer in DNA, here’s what’s making the headlines in the cancer space this week.
 
Jessica Skarzynski
Here is a roundup of the latest news and updates for patients with Chronic Lymphocytic Leukemia from CURE.
Ryan McDonald
“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×